Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Excipient Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

NCT03836859
View directory record Official record
Conditions
Healthy Volunteers
Interventions
rhNGF 20μg/mL, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 5, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional

INvestigating TELmisartin Study

NCT04715763
View directory record Official record
Conditions
Covid19
Interventions
Telmisartan Oral Product, Placebo
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 5, 2026, 4:35 PM EDT
Terminated Phase 3 Interventional Results available

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

NCT02626455
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 5, 2026, 4:35 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized, Double-Blind Study to Assess the Effect of a Postbiotic on Oxidative Stress and Exercise Performance

NCT06795425
View directory record Official record
Conditions
Oxidative Stress, Healthy, Exercise-induced Muscle Damage, Exercise-induced Muscle Soreness, Immune Function, Gut Health, Microbiome Analysis, Exercise Performance, Exercise Metabolism
Interventions
Postbiotic Active Lifestyle Blend, Placebo
Dietary Supplement · Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 5, 2026, 4:35 PM EDT
Not yet recruiting Not applicable Interventional

Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women

NCT07406243
View directory record Official record
Conditions
Aging, Postmenopause
Interventions
Mitoquinone (MitoQ), Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
60 Years and older · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae

NCT02294682
View directory record Official record
Conditions
Gonorrhea
Interventions
GSK2140944
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Fountain Valley, California • Los Angeles, California • Palm Springs, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Citicoline for Bipolar 1 Disorder and Cocaine Dependence

NCT00619723
View directory record Official record
Conditions
Bipolar Disorder, Cocaine Dependence
Interventions
Citicoline, Placebo, Cognitive Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis

NCT02709005
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
5% Monolaurin Vaginal Gel, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Iowa City, Iowa • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT04615273
View directory record Official record
Conditions
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin, Placebo, Somatropin
Drug · Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 80 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

NCT02974907
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 5, 2026, 4:35 PM EDT
Not listed Phase 2 Interventional

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

NCT04905836
View directory record Official record
Conditions
Covid19
Interventions
COVI-MSC, Placebo
Biological · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Brandon, Florida • Sarasota, Florida • Boise, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 5, 2026, 4:35 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

NCT04984278
View directory record Official record
Conditions
Spasticity With Multiple Sclerosis
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

NCT01262651
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols, Placebo (GA-0034)
Drug
Lead sponsor
GW Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
25
States / cities
Phoenix, Arizona • El Cajon, California • Gilroy, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 4 Interventional Results available

A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia

NCT05597020
View directory record Official record
Conditions
Insomnia Disorder, Nocturia
Interventions
Daridorexant, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Miami Beach, Florida • Pompano Beach, Florida • Weston, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 5, 2026, 4:35 PM EDT
Recruiting Phase 3 Interventional

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

NCT07246590
View directory record Official record
Conditions
Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions
VP-102, Vehicle
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Saint Augustine, Florida • Plainfield, Indiana • Hunt Valley, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Microneedle Patch Study in Healthy Infants/Young Children

NCT03207763
View directory record Official record
Conditions
Vaccination, Skin Absorption
Interventions
Microneedle Formulation 1, Microneedle Formulation 2
Device
Lead sponsor
Emory University
Other
Eligibility
6 Weeks to 24 Months
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 5, 2026, 4:35 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

NCT04203498
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Port Charlotte, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whole Coffee Cherry Study

NCT04986956
View directory record Official record
Conditions
Effect of Drug
Interventions
Whole coffee cherry extract, Placebo
Dietary Supplement
Lead sponsor
Auburn University
Other
Eligibility
40 Years to 65 Years
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream

NCT05514353
View directory record Official record
Conditions
Healthy Volunteers, Psoriasis
Interventions
PBI-100 Topical Cream, Vehicle Cream
Drug
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

NCT04304144
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program

NCT05878119
View directory record Official record
Conditions
Healthy
Interventions
Investigational Product - MIB 626, Placebo, Standardized, progressive, high intensity, multidimensional exercise, Usual Physical Activity
Drug · Other
Lead sponsor
Metro International Biotech, LLC
Industry
Eligibility
19 Years to 40 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of CDD-2101 in Health Volunteers

NCT06570668
View directory record Official record
Conditions
Constipation - Functional
Interventions
CDD-2101
Drug
Lead sponsor
Centre for Chinese Herbal Medicine Drug Development Limited
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Sep 5, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

NCT05667662
View directory record Official record
Conditions
ABPA
Interventions
Itraconazole Powder, Placebo
Drug
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 5, 2026, 4:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers

NCT02530710
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Q203, Placebo
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 5, 2026, 4:35 PM EDT